Trials / Unknown
UnknownNCT03549182
Serotonin, Serotonin Genetics(TPH2) and Emotion and Interference Processing
The Influence of Acute Tryptophan Depletion on Emotion and Interference Processing and Potential Moderation by 5HT Genetics (TPH2)
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- Sponsor
- University of Electronic Science and Technology of China · Academic / Other
- Sex
- Male
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
The study aims to explore whether acute tryptophan depletion can affect the emotion and interference processing whether this effect is moderated by the TPH2 genotype
Detailed description
Based on previous studies suggesting that serotonin, a neurotransmitter, is associated with social \& emotional behavior, including emotional reactivity and emotion regulation, the present study aims to explore effects of acute tryptophan depletion (ATD) on emotion processing and emotional interference processing within a randomized double-blind, with-subject, placebo-controlled pharmaco-fMRI experiment. To further examine the potential moderating effects of the genetic makeup of the serotonin system the present study will include a pharmacogenetics imaging approach. Given that TPH2 is the key regulator of the serotonergic signaling pathway, we therefore assessed whether such the effects of tryptophan depletion vary according to the TPH2 genotype. To this end, healthy male TPH2-GG or TPH2-TT carriers will be recruited and will receive ATD (100g) and placebo (102.3g) in a within subject design. To control for potential effects of pre-medication personality traits as well as effects of medicines on mood, subjects will be administered pre-treatment assessing relevant personality traits and post-treatment assessments of mood.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ATD treatment | oral administration of ATD (100g)(Acute Tryptophan Depletion) |
| DRUG | placebo treatment | oral administration of placebo (102.3g) |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2021-06-01
- Completion
- 2021-12-01
- First posted
- 2018-06-07
- Last updated
- 2020-12-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03549182. Inclusion in this directory is not an endorsement.